Browse By Last Name
Bruce K. Dallas

A member of Davis Polk’s Corporate Department, Mr. Dallas is a founding partner of the Menlo Park office. He advises on corporate finance, derivatives, SEC disclosure and corporate governance. His transactional work includes initial public offerings (with an emphasis on bio-tech and high-tech companies), high-yield, convertible and straight debt offerings and issuer repurchase programs.  

Mr. Dallas has been the primary capital markets partner for Comcast, E*TRADE, Leidos, MASCO, NBCUniversal, Oracle, Roper Industries, Science Applications International Corporation and Texas Instruments. He also regularly represents leading underwriters. Mr. Dallas authored three recent SEC no-action letters, two for Comcast permitting its then 51% subsidiary, NBCUniversal, to be treated as wholly owned for purposes of reduced SEC periodic reporting, one confirming this relief following the acquisition form GE and one for SAIC permitting it to use Rule 14a-16 (Notice and Access) for the pending collapse of its holding company structure.

Work Highlights

Recent Transactions
  • Comcast’s $16.7 billion acquisition of GE’s interest in NBCUniversal, including the related $4.7 billion of debt and preferred stock financing at the 3(c)(7) investment company exempt issuer, NBCUniversal Enterprise, Inc.
  • Comcast’s $45.2 billion pending merger with Time Warner Cable.
  • An aggregate of $26 billion in public debt offerings representing Comcast, Masco, NBCUniversal, Oracle, Roper and Texas Instruments
  • An aggregate of $1.2 billion in debt exchange offers representing Universal Orlando and SAIC
  • An aggregate of $3.1 billion in convertible notes offerings by Cepheid, Depomed, Electronics for Imaging, Horizon Pharma, Infinera, JDS Uniphase, Move Inc., Palo Alto Networks and ServiceNow 
  • Initial public offerings by Achaogen, Adamas Pharmaceuticals, Atara Biotherapeutics, AVG Technologies, BIND Therapeutics, Endocyte, Esperion Therapeutics, Loxo Oncology, Palo Alto Networks, Portola Pharmaceuticals, Revance Therapeutics, Versartis and Xencor 

  • Equity offerings by Affymax, Amylin Pharmaceuticals, Endocyte, Esperion Therapeutics, Geron, Jazz Pharmaceuticals, Onyx Pharmaceuticals and Xenoport


Listed as a leading lawyer in several legal industry publications, including:

  • Band 1, California: Capital Markets: Debt & Equity – Chambers USA, every year since the inaugural issue in 2007 
  • Chambers Global: The World’s Leading Lawyers for Business
  • IFLR1000
  • Law Business Research’s Who’s Who Legal: California
  • Legal Media Group’s Expert Guide to the World’s Leading Capital Markets Lawyers
  • Daily Journal’s “Top 100 Lawyers” list for California
  • The Legal 500 U.S.

Of Note

Speaking Engagements
  • PLI: Drafting Securities Filings, 2010, 2011, 2012, 2013 and 2014
  • Northwestern Law School: 37th and 40th Annual Securities Regulation Institutes
  • Society of Corporate Secretaries & Governance Professionals, 2009 National Conference  

Professional History

  • Partner, 1994-present
  • Associate, 1985-1994
  • Law Clerk, Hon. Harry W. Wellford, U.S. Court of Appeals, Sixth Circuit, 1984-1985


  • 1600 El Camino Real
    Menlo Park, CA 94025
    P: 650-752-2022
    F: 650-752-3622

Bar Admissions

  • State of California
  • State of New York
  • U.S. Court of Appeals, Sixth Circuit


  • A.M., Dartmouth College, 1979
  • A.B., Chemistry, Dartmouth College, 1979
  • J.D., Vanderbilt University Law School, 1984
    • Order of the Coif
    • Articles Editor, Law Review
  • M.B.A., Vanderbilt University, Owen Graduate School of Management, 1984
    • Beta Gamma Sigma Honor Society